Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis
2023-504964-41-00Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Dec 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 5
01
Overview
Phase 2 trial of SRP-1002 in idiopathic pulmonary fibrosis (IPF), sponsored by Arrowhead Pharmaceuticals. Started Dec 2023; status: completed.
02
Drugs
SRP-1002
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2023-504964-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504964-41-00.